NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies

Molecular Cancer Therapeutics

Volumn 11, Issue 4, 2012, Pages 1006-1016

  Valsasina, Barbara ^a   Beria, Italo ^a   Alli, Cristina ^a   Alzani, Rachele ^a   Avanzi, Nilla ^a   Ballinari, Dario ^a   Cappella, Paolo ^a   Caruso, Michele ^a   Casolaro, Alessia ^a   Ciavolella, Antonella ^a   Cucchi, Ulisse ^a   De Ponti, Anna ^a   Felder, Eduard ^a   Fiorentini, Francesco ^b   Galvani, Arturo ^a   Gianellini, Laura M ^a   Giorgini, Maria L ^a   Isacchi, Antonella ^a   Lansen, Jaqueline ^b   Pesenti, Enrico ^a   Rizzi, Simona ^a   Rocchetti, Maurizio ^b   Sola, Francesco ^a   Moll, Jürgen ^a   more..

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b Accelera Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IRINOTECAN; NMS P937; PACLITAXEL; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; COLON ADENOCARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IC 50; MITOSIS; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL TIME; TUMOR GROWTH; TUMOR REGRESSION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOGS; FEMALE; HAPLORHINI; HL-60 CELLS; HUMANS; LEUKEMIA; MICE; MICE, NUDE; MICE, SCID; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; QUINAZOLINES; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862734370     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0765     Document Type: Article

References (42)

1. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9:643-60.
2. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5:429-40. (Pubitemid 38745493)
3. Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004;3:641-6. (Pubitemid 39193743)
4. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003;94:148-52. (Pubitemid 36575873)
5. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004;60:240-5. (Pubitemid 38971835)
6. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004;90:815-21. (Pubitemid 38406592)
7. Weichert W, Kristiansen G,Winzer KJ, Schmidt M, Gekeler V, Noske A, et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005;446: 442-50. (Pubitemid 40674853)
8. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999;59: ]2794-7.
9. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007;67:10148-58. (Pubitemid 350070786)
10. Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009;129:2843-53.
11. Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009;23:1564-76.
12. Renner AG, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009;114:659-62.
13. Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokoyama S. Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 2005;46:225-31. (Pubitemid 40185952)
14. Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, et al. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003;22:69-80. (Pubitemid 36152885)
15. Matthess Y, Kappel S, Spankuch B, Zimmer B, Kaufmann M, Strebhardt K. Conditional inhibition of cancer cell proliferation by tetracycline- responsive, H1 promoter-driven silencing of PLK1. Oncogene 2005;24:2973-80. (Pubitemid 40675528)
16. Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T, et al. A spindle checkpoint arrest and a cytokinesis failure by the dominantnegative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 2002;277:32282-93. (Pubitemid 34969045)
17. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006;26:2093-108. (Pubitemid 43346913)
18. Seeburg DP, Pak D, Sheng M. Polo-like kinases in the nervous system. Oncogene 2005;24:292-8. (Pubitemid 40188610)
19. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10:825-41.
20. Beria I, Valsasina B, Brasca MG, Ceccarelli W, Colombo M, Cribioli, et al. 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors. Bioorg Med Chem Lett 2010;20:6489-94.
21. Beria I, Ballinari D, Bertrand JA, Borghi D, Bossi RT, Brasca MG, et al. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. J Med Chem 2010;53:3532-51.
22. Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R, Patton V, et al. Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Res 2010;30:4973-85.
23. Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, et al. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol 2009;24:879-91.
24. Beria I, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 2011;21:2969-74.
25. Van Vugt MA, Medema RH. Checkpoint adaptation and recovery: back with Polo after the break. Cell Cycle 2004;3:1383-6. (Pubitemid 40310672)
26. Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I. Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 2007;43:1862-8. (Pubitemid 47243652)
27. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803.
28. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubulestabilizing agents. J Clin Oncol 2006;24:1633-42. (Pubitemid 46638788)
29. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17. (Pubitemid 46160987)
30. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559-70.
31. Hofheinz RD, Al-Batran SE, Hochhaus A, Jager E, Reichardt VL, Fritsch H, et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010;16:4666-74.
32. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15:3094-102.
33. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005;24:260-6. (Pubitemid 40188606)
34. Benetatos L, Dasoula A, Hatzimichael E, Syed N, Voukelatou M, Dranitsaris G, et al. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol 2011;9:1037-45.
35. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008;105:15535-40.
36. Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L, et al. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 2006;107:250-6. (Pubitemid 43053549)
37. Yang Y, Bai J, Shen R, Brown SA, Komissarova E, Huang, et al. Pololike kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 2008;68:4077-85.
38. Olmos D, Swanton C, de Bono J. Targeting polo-like kinase: learning too little too late? J Clin Oncol 2008;26:5497-9.
39. Soto E, Staab A, Freiwald M, Munzert G, Fritsch H, Doge C, et al. Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. Clin Pharmacol Ther 2010;88:660-7.
40. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
41. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009;106:3964-9.
42. Christoph DC, Schuler M. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies. Expert Rev Anticancer Ther 2011;11:1115-30.